Gross-Goupil M - Search Results

1

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.

de Vries-Brilland M, Rioux-Leclercq N, Meylan M, Dauvé J, Passot C, Spirina-Menand E, Flippot R, Fromont G, Gravis G, Geoffrois L, Chevreau C, Rolland F, Blanc E, Lefort F, Ravaud A, Gross-Goupil M, Escudier B, Negrier S, Albiges L. de Vries-Brilland M, et al. Among authors: gross goupil m. J Immunother Cancer. 2023 Nov;11(11):e006885. doi: 10.1136/jitc-2023-006885. J Immunother Cancer. 2023. PMID: 37935564 Free PMC article.

2

[Revolution in treatment of renal carcinoma: molecular rational and clinical approach].

Escudier B, Gross-Goupil M. Escudier B, et al. Med Sci (Paris). 2008 Aug-Sep;24(8-9):697-9. doi: 10.1051/medsci/20082489697. Med Sci (Paris). 2008. PMID: 18789213 Free article. French. No abstract available.

3

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

4

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.

5

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B. Michels J, et al. Invest New Drugs. 2010 Oct;28(5):690-3. doi: 10.1007/s10637-009-9275-z. Epub 2009 Jun 24. Invest New Drugs. 2010. PMID: 19547920

6

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus.

Massard C, Fizazi K, Gross-Goupil M, Escudier B. Massard C, et al. Invest New Drugs. 2010 Dec;28(6):879-81. doi: 10.1007/s10637-009-9295-8. Epub 2009 Aug 1. Invest New Drugs. 2010. PMID: 19649567 No abstract available.

7

Incidence of brain metastases in renal cell carcinoma treated with sorafenib.

Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Massard C, et al. Ann Oncol. 2010 May;21(5):1027-31. doi: 10.1093/annonc/mdp411. Epub 2009 Oct 22. Ann Oncol. 2010. PMID: 19850637 Free article. Clinical Trial.

8

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 Free article. French.

9

Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.

Ravaud A, Grossgoupil M. Ravaud A, et al. Lancet Oncol. 2010 Apr;11(4):307-8. doi: 10.1016/S1470-2045(10)70043-7. Lancet Oncol. 2010. PMID: 20359658 No abstract available.

10

[Renal cell carcinoma management and therapies in 2010].

Albouy B, Gross Goupil M, Escudier B, Massard C. Albouy B, et al. Bull Cancer. 2010;97:17-28. doi: 10.1684/bdc.2010.1067. Bull Cancer. 2010. PMID: 20418201 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

174 results

Search Page